HomeAI · summaries
Storia in 4 fonti
AbCellera Biologics Menopause Drug Data Shows 'New Efficacy Benchmark' - AbCellera Biologics (NASDAQ:ABCL
AbCellera reports positive Phase 2 clinical trial results for ABCL635, a single-dose treatment for menopausal hot flashes.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and…
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a…
- ·
endpoints.news
AbCellera details 'striking' Phase 2 data for vasomotor symptoms treatment
AbCellera's $ABCL surged 38% after ABCL635 cut hot flash frequency 50% over placebo in Phase 2, outperforming Astellas' Veozah and Bayer's Lynkuet.
